Checkout
Humira Competitors Have CVS Wrestling With Complex Calculations
- Top-selling AbbVie medicine will soon have copycat versions
- Drug-benefits manager is still weighing approach to coverage
CVS manages prescription benefits for more than 110 million people.
Photographer: Nora Savosnick/BloombergThis article is for subscribers only.
CVS Health Corp., the largest prescription benefits provider in the US, is still deciding on its approach to covering one of the world’s best-selling drugs, Humira, as a competing version is set to hit the market at the end of this month.
The decision could have billion-dollar consequences for AbbVie Inc., maker of the anti-inflammatory injection. It will also affect rivals such as Amgen Inc. that aim to displace Humira with nearly identical drugs known as biosimilars.